ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder(s) of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s). Alembic Pharma: EIR certificate bodes well
Aleor Dermaceuticals, a 60:40 joint venture between Alembic Pharmaceuticals and Orbicular Pharmaceutical Technologies Pvt Ltd, has received an establ ALEMBIC PHARMACEUTICALS LTD. - 533573 - Alembic Pharmaceuticals Limited Announces Its Joint Venture, Aleor Dermaceuticals Ltd., Received Establishment Inspection Report (EIR) For Its Formulation Facility At Karkhadi.
This is to inform the exchange that Aleor Dermaceuticals Ltd. (Aleor), a 60:40 Joint Venture between Alembic Pharmaceuticals Ltd (Alembic) and Orbicular Pharmaceutical Technologies Pvt. Ltd. (Orbicular), has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection carried out by them at Aleor''s Formulation Facility at Karakhadi, Gujarat, India during the period from 16th September, 2019 to 20th September, 2019. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates published by the Company on behalf of the shareholder(s) and / or legal heir(s) of the registered shareholder(s) in English language newspaper - Business Standard on 4th December, 2019. Company news: Alembic Pharmaceuticals
Alembic Pharmaceuticals on Monday announced that its joint venture Aleor Dermaceuticals (Aleor) has received tentative approval from the US Food & ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's joint venture, Aleor Dermaceuticals Limited, has received US Food and Drug Administration (USFDA) Tentative Approval for Diclofenac Sodium Topical Solution USP, 2% w/w. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for Silodosin Capsules, 4 mg and 8 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. Company news: Alembic Pharmaceuticals
Alembic Pharmaceuticals on Friday said it has received approvals from the United States Food and Drug Administration for its Deferasirox tablets in th ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for its following Abbreviated New Drug Applications (ANDAs): 1. Final Approval for Deferasirox Tablets 90 mg and 360 mg. 2. Final Approval for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg, and 500 mg. 3. Tentative Approval for Deferasirox Tablets 180 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosures Requirements) Regulations, 2015 ('Listing Regulations, 2015')
Pursuant to Regulation 23(9) of the Listing Regulations, 2015, we enclose herewith Disclosure of Related Party Transactions, on a consolidated basis, for the period ended 30th September, 2019. We request you to kindly take the same on record.